Irbesartan Aurovitas (Irbesartan)

Irbesartan belongs to the angiotensin II receptor blocker class and is employed in several cardiovascular and renal disease pathways.

• Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Heart failure: improves symptoms and decreases hospitalisation rates in patients with reduced ejection fraction.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This inhibition leads to reduced peripheral resistance, lower blood volume, and ultimately a decrease in arterial blood pressure, while also providing renal protective effects.

Adverse reactions may occur with Irbesartan therapy.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Headache, often mild to moderate in intensity.
• Fatigue or general weakness.
• Elevated serum potassium levels.
• Nasal congestion or upper respiratory discomfort.

Serious or Rare Side Effects

• Angioedema involving the face, lips, tongue or airway.
• Acute kidney injury or significant rise in serum creatinine.
• Severe hypotension leading to syncope.
• Hepatic injury manifested by jaundice or elevated liver enzymes.

Before initiating Irbesartan, several safety considerations should be observed.

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Renal function assessment: check serum creatinine and eGFR periodically.
• Serum potassium: monitor for hyperkalaemia, especially when combined with potassium‑sparing agents.
• Pregnancy: discontinue if pregnancy is confirmed; the drug is contraindicated (Category D).
• Hepatic impairment: use with caution and adjust therapy as needed.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use can increase the risk of renal dysfunction.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• ACE inhibitors: concurrent use raises the chance of severe hypotension and hyperkalaemia.
• NSAIDs (e.g., ibuprofen, naproxen): can impair renal function and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance antihypertensive response, requiring dose adjustment.
• Lithium: increased lithium levels may lead to toxicity.
• Cyclosporine or tacrolimus: may raise serum creatinine, necessitating renal monitoring.